A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Saved in:
| Title: | A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. |
|---|---|
| Authors: | Senapati J; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Muftuoglu M; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Ishizawa J; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Abbas HA; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Yilmaz M; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Dara SI; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Basyal M; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Li L; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Naqvi K; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Pourebrahim R; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Jabbour EJ; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Kornblau SM; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Khoury J; Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org., DiNardo CD; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. cdinardo@mdanderson.org. |
| Source: | Blood cancer journal [Blood Cancer J] 2023 Jun 29; Vol. 13 (1), pp. 101. Date of Electronic Publication: 2023 Jun 29. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-023-00871-1 |
